Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 17/02/2021 Messerer_Bild_2.jpg

    Whole blood model enables development of early warning system for sepsis

    Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…

    https:////www.gesundheitsindustrie-bw.de:443/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Infection control - 07/01/2021 Elektronenmikroskopische Aufnahme von pink gefärbten Staphylococcus aureus Bakterien auf einer lila gefärbten Zelloberfläche.

    Gene accordions as potential markers for pathogenic properties

    Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
  • Press release - 17/11/2020

    The Long Road to Dementia

    The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
  • Press release - 02/11/2020

    Juvenile myelomonocytic leukemia: International classification model allows for customized treatment

    Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
  • Press release - 31/08/2020

    Radiology researcher receives Humboldt Foundation Sofja Kovalevskaja Award

    Dr. André Martins from the Department of Radiology at the Tübingen University Hospitals is one of this year's recipients of the Alexander von Humboldt Foundation's Sofja Kovalevskaja Award.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/radiology-researcher-receives-humboldt-foundation-sofja-kovalevskaja-award
  • Press release - 27/04/2020

    EIT Health pledges €6m funding to accelerate COVID-19 solutions

    EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
  • New edition - 24/05/2019 Magnetic resonance image of brain metastases.

    Tumour metastasis

    Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
  • Article - 16/04/2019 20190218_Foto_Labor_Quelle_UniversitNatsklinikum_Heidelberg.jpg

    Tumour monitoring using liquid biopsy

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Biosensor - 13/11/2018 Schematic showing the workflow that is required for obtaining a test result with paper strip, pipette, darkness and camera. A test result showing circles with different shades of blue and red.

    Rapid medical test for at-home use

    For quite a number of illnesses, patients need to have the concentrations of the medications they are taking and their blood metabolites checked on a regular basis, which can make life rather difficult. Researchers at the Max Planck Institute for Medical Research in Heidelberg have now developed a test based on the firefly enzyme luciferase. This enzyme can be used to quickly and cheaply measure parameters of interest.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/rapid-medical-test-for-at-home-use
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Press release - 04/10/2017

    Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

    Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
  • Press release - 05/09/2017 PET-Gerat-Uni-Tubingen.jpg

    Cell marking opens up a window into the body

    A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cell-marking-opens-up-a-window-into-the-body
  • Article - 04/07/2017 The photo shows Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser at the award ceremony.

    Ruxolitinib – successful graft-versus-host disease treatment

    Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ruxolitinib-successful-graft-versus-host-disease-treatment
  • Press release - 24/05/2017

    High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures

    High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/high-tech-gruenderfonds-htgf-invests-in-reutlingen-based-signatope-gmbh-safe-medications-thanks-to-new-test-procedures
  • Article - 18/05/2017 The photo shows a pipette with which drinking water is applied to the ImmuStick.

    ImmuStick – novel rapid test for identifying disease pathogens

    In some situations such as in the food and pharmaceutical industries or hospitals, a test to identify disease pathogens can be vital. At present, such tests are relatively time-consuming and can take hours or even days to produce results, depending on the pathogen. Scientists from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart are currently developing a rapid test called ImmuStick which is as easy to use…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/immustick-novel-rapid-test-for-identifying-disease-pathogens
  • Article - 31/03/2017 Blue-white longish plastic measurement device.

    Bosch to enter the medical technology sector – start-up culture meets proven expertise

    Many of us have known the Bosch Group mainly as a technology company that is active in the automotive sector. Now, the multinational company is opening up a whole new field of business and is entering the medical technology market with a new subsidiary. Bosch Healthcare Solutions GmbH, which is headquartered in the city of Waiblingen, has developed an innovative breath analysis device that allows asthmatics to measure the severity of airway…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/bosch-to-enter-the-medical-technology-sector-start-up-culture-meets-proven-expertise
  • Article - 27/02/2017 Prof-Michael-Baumann.jpg

    Michael Baumann – the new man at the helm of the DKFZ

    On 1st November 2016, Professor Michael Baumann, a radiation oncologist from Dresden, became the new chairman and scientific director of the German Cancer Research Center in Heidelberg. Michael Baumann has the perfect background when it comes to combining basic and applied cancer research. This enables scientific findings to be used more quickly and effectively for preventing, diagnosing and treating cancer, and patients’ individual needs to be…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-baumann-the-new-man-at-the-helm-of-the-dkfz
  • Article - 21/12/2016 Signatope GmbH’s founding team (from left to right) Prof. Dr. Hugo Hämmerle, Dr. Oliver Pötz, Dr. Hannes Planatscher, Dr. Octavian Schatz and Dr. Thomas Joos.

    For all types of tests: Signatope’s biomarker assays

    Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
  • Article - 13/12/2016 The sensor was developed at the Institute of Analytical and Bioanalytical Chemistry

    Smart sensor technology from Ulm can do more than just breath analysis

    Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • BioLAGO and BIOPRO to start new diagnostics project - 07/07/2016 Biolag_Biopro_Workshop1.jpg

    DiagNeeds: translating clinical requirements into new products

    (Lake Constance/Stuttgart) – BioLAGO e.V. and BIOPRO Baden-Württemberg GmbH are working together on the “DiagNeeds” project to bring hospitals and medical professionals closer to diagnostics providers in order to facilitate the development of new diagnostic procedures. There will be special focus on topics that are currently of major interest in the field of diagnostics, including liquid biopsies, companion diagnostics, point-of-care diagnostics…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/diagneeds-klinik-bedarfe-in-neue-produkte-uebersetzen
  • Article - 25/04/2016 Trumpp_Andreas.jpg

    Pancreatic cancer and its resistance to therapy

    Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy

Page 1 / 5

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search